TRACLEER® [bosentan[removed]mg and 125 mg film-coated tablets Use of TRACLEER® requires attention to two significant concerns: 1) potential for serious liver injury, and 2) potential damage to a fetus.

First Page		Document Content
Date: 2009-03-31 14:51:02 Medicine Alcohols Pyrimidines Bosentan Organochlorides Sitaxentan Endothelin receptor antagonist Pulmonary hypertension Nitrazepam Chemistry Organic chemistry Sulfonamides		TRACLEER® [bosentan[removed]mg and 125 mg film-coated tablets Use of TRACLEER® requires attention to two significant concerns: 1) potential for serious liver injury, and 2) potential damage to a fetus. Add to Reading List Source URL: www.accessdata.fda.gov Download Document from Source Website File Size: 394,73 KB Share Document on Facebook

	TRIUMPH I study: Double Blind Placebo Controlled Clinical Investigation into the Efficacy and Tolerability of Inhaled Treprostinil Sodium in Patients with Severe Pulmonary Arterial Hypertension DocID: 1oueC - View Document
	Clinical Commissioning Policy: Clinical Commissioning Policy: National policy for targeted DocID: 18zFu - View Document
	DOCX Document DocID: 16jAU - View Document
	Kwartaalbericht 4e kwartaalNovember 2005 Contents DocID: 15SVk - View Document
	ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. DocID: 15hh8 - View Document